The North America Blood Glucose Monitoring System Market is witnessing rapid advancements driven by the increasing prevalence of diabetes, technological innovations, and favorable reimbursement policies. Valued at USD 6,200 Million in 2025, the market is projected to reach USD 14,900 Million by 2035, expanding at a CAGR of approximately 8.8% from 2024 to 2035.
The economic impact of tariffs on "North America Blood Glucose Monitoring System Market".
Market Growth Drivers
Increasing Prevalence of Diabetes: Rising rates of diabetes, estimated at over 37 million Americans affected as of the CDC’s latest statistics, fuel demand for more efficient glucose monitoring in both type 1 and type 2 populations. The surge in incidence translates directly into a need for continuous blood sugar monitoring, driving adoption rates for systems produced by major market players such as Abbott and Dexcom.
Technological Advancements in Monitoring Devices: The integration of IoT, smartphone connectivity, and minimally invasive technology has revolutionized the blood glucose monitoring landscape. Abbott Laboratories, for example, has launched the FreeStyle Libre 3, featuring real-time glucose monitoring via smartphone, improving patient compliance and outcomes, and fostering substantial growth in this market segment.
Market Trends
Shift Towards Continuous Glucose Monitoring (CGM): There is a pronounced shift from traditional self-monitoring blood glucose (SMBG) systems to continuous glucose monitors (CGMs). CGM systems provide real-time readings and alerts, significantly improving glycemic control and patient lifestyle. Dexcom’s G7 CGM, launched in 2024, demonstrates this trend, with its compact design, 30-minute warm-up, and compatibility with various digital health platforms.
Integration with Digital Health Ecosystem: The proliferation of interoperable digital tools is enabling seamless data sharing and remote monitoring. With Medtronic’s Guardian Connect integrated into telehealth solutions, patients and healthcare professionals are leveraging cloud-based platforms for better insights, predictive alerts, and tailored care—reflecting the digital transformation shaping the blood glucose monitoring space.
Market Opportunities
Expansion in Untapped Rural and Geriatric Segments: Companies like Roche are actively targeting rural healthcare facilities and the aging population with tailored support, education, and easy-to-use monitoring solutions, aiming to increase penetration and compliance rates.
Growth in Personalized Diabetes Management: The rising trend of personalized healthcare, highlighted by Ascensia Diabetes Care’s partnerships for individualized digital coaching, presents significant opportunities for customized blood glucose monitoring and intervention.
North America Blood Glucose Monitoring System Market Revenue (USD Million), 2020-2035
The market revenue chart demonstrates consistent growth from 2020 to 2035. Starting at USD 3,300 Million in 2020, the market shows a steady uptick as diabetes incidence rises and technological innovations like continuous glucose monitoring and digital integration become mainstream. By 2025, revenue reaches USD 6,200 Million, with an accelerated CAGR as adoption broadens and health awareness increases. Projections indicate a surge to USD 14,900 Million in 2035, underscoring continued market expansion driven by both clinical need and advances in non-invasive and real-time monitoring solutions.
North America Blood Glucose Monitoring System Market by Region, 2025
In 2025, the US dominates the North America Blood Glucose Monitoring System Market, accounting for 78% of the market, driven by advanced healthcare infrastructure and high diabetes prevalence. Canada follows with an 18% share, supported by growing public awareness and regulatory approvals. Mexico holds a modest 3%, with limited penetration of advanced technology but rising healthcare investment. Other regions, comprising less than 1% each, reflect slower adoption rates. Together, these figures highlight the significance of the US market and the evolving opportunities in Canada and Mexico.
Recent Developments
In May 2024, Abbott Laboratories announced the FDA clearance for its FreeStyle Libre 3 system in the US, featuring the world’s smallest and thinnest sensor for continuous glucose monitoring. The device offers real-time glucose readings and seamless smartphone integration, aiming to enhance user comfort and data accessibility.
In March 2024, Dexcom introduced its G7 Continuous Glucose Monitoring system in Canada. Its advanced features, including a shorter warm-up time and improved accuracy, make it increasingly popular among both adult and pediatric diabetes patients, strengthening Dexcom’s competitive positioning in North America.
In April 2024, Medtronic integrated its Guardian Connect CGM system with leading telemedicine platforms, enabling clinicians to remotely monitor and analyze patient data. This move addresses the growing need for remote management solutions amidst rising virtual care adoption post-pandemic.
Press Releases